Logo

Gilead Entered into a Research Collaboration with Dragonfly to Develop Natural Killer Cell Engagers for Oncology and Inflammation Indications

Share this
Gilead Entered into a Research Collaboration with Dragonfly to Develop Natural Killer Cell Engagers for Oncology and Inflammation Indications

Gilead Entered into a Research Collaboration with Dragonfly to Develop Natural Killer Cell Engagers for Oncology and Inflammation Indications

Shots:

  • Dragonfly to receive $300M up front, opt-in fees & performance-based development, regulatory & commercial milestones along with 20% royalties globally. Gilead to get an exclusive global license for DF7001 (5T4-targeting NK cell engager )
  • After completion of preclinical activities, Gilead has an option to get license rights globally for the development & commercialization of an additional NK cell engager programs using Dragonfly’s TriNKET platform
  • DF7001 can activate & direct NK and cytotoxic T cell killing against cancer cells & will trigger the killing of 5T4+ expressing cells including tumor cells, cancer-associated fibroblasts & cancer stem cells. The company plans to file an IND application of DF7001 in H1’23

Ref: Gilead | Image: Gilead 

Click here to­ read the full press release 

Neha

Neha Madan is a content writer at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions